Curated News
By: NewsRamp Editorial Staff
August 13, 2026

SS Innovations Surges with Record Q2 Revenue and 30% System Installations

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • SS Innovations International's revenue surged 39.4% to $13.9M, showcasing strong growth potential for investors.
  • SSi Mantra installations rose 30.4% to 30, with gross margin 50.9%, and FDA review expected by Q1 2027.
  • Robotic telesurgery spanning 13,600 miles between Colombia and India makes surgical expertise accessible globally.
  • The SSi Mantra system completed 12,272 procedures, including 175 telesurgeries, across 12 countries.

Impact - Why it Matters

This news matters because SS Innovations' robust growth and regulatory progress indicate that affordable robotic surgery is becoming more accessible worldwide. The successful telesurgery over 13,600 miles demonstrates the potential of remote surgery to bridge healthcare gaps, especially in underserved regions. As the company moves closer to FDA clearance and CE marking, it could disrupt the surgical robotics market, offering a cost-effective alternative to established players. For investors, the strong financial performance and expanding installed base signal promising long-term prospects, while for patients and healthcare providers, it could mean increased access to advanced surgical care at lower costs.

Summary

SS Innovations International (NASDAQ: SSII) has announced record financial results for the second quarter of 2026, with revenue surging 39.4% to $13.9 million compared to $10 million in the same period last year. The growth was driven by a 30.4% increase in installations of its SSi Mantra surgical robotic system, reaching 30 units during the quarter. Gross profit climbed 20% to $7.1 million, yielding a gross margin of 50.9%. The company reported a net loss of $2.7 million, or $0.01 per diluted share, versus a net loss of $0.3 million a year earlier. For the first half of the fiscal year, revenue jumped 65.6% to $25 million, with installations up 47.4% to 56 systems. As of June 30, SS Innovations held $13.6 million in cash and cash equivalents, with no long-term debt and a cumulative installed base of 224 SSi Mantra systems across 12 countries.

The company has also achieved significant clinical milestones, with 12,272 cumulative procedures performed using the SSi Mantra by June 30, including 175 telesurgeries. Notably, SS Innovations completed a robotic telesurgery spanning over 13,600 miles between Colombia and India, showcasing the system's remote capabilities. Looking ahead, the company anticipates that the U.S. Food and Drug Administration will complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027, and it believes it can secure European Union CE marking certification by the end of 2026. These regulatory advancements are pivotal for expanding into major markets.

SS Innovations is dedicated to making robotic surgery affordable and accessible globally, offering the SSi Mantra system and a suite of SSi Mudra surgical instruments. Headquartered in India but incorporated in the United States, the company plans to broaden its global footprint with its cost-effective solutions. The full press release is available at https://ibn.fm/nTMso. For more updates, investors can visit the company's newsroom at https://ibn.fm/SSII.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations Surges with Record Q2 Revenue and 30% System Installations

Blockchain registration record for this content